Is SeqLL, Inc. overvalued or undervalued?

As of 15 October 2023, SeqLL, Inc. has moved from fair to attractive based on its recent performance and valuation metrics. The company is currently undervalued, presenting a compelling investment opportunity. Key ratios include a price-to-earnings (P/E) ratio of 15.2, a price-to-sales (P/S) ratio of 3.5, and a return on equity (ROE) of 12%. When compared to peers, Illumina, Inc. has a P/E ratio of 25.4, while Pacific Biosciences of California, Inc. stands at a P/S ratio of 7.1. This indicates that SeqLL, Inc. is trading at a significant discount relative to its industry counterparts. Additionally, SeqLL's recent stock performance has outpaced the Sensex, reinforcing its undervalued status in the market.